TABLE 4.
Discrepant VirClia and Platelia GM assay resultsa
| Patient no. | Patient identification | Underlying disease | Radiological finding(s) | Serum EIA ODIb | BAL fluid results |
EORTC/MSGERC 2020 classification (excluding GM) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Direct microscopy | Culture | Aspergillus PCR | EIA ODI | CLIA ODI | ||||||
| 1 | A013 | AML | Nodules, halo | 0.1 | Negative | Negative | Positive (single PCR) | 0.1 | 0.24 | Possible IPA |
| 2 | B004 | NK-T lymphoma | Nodules, halo | 0.1 | Negative | Negative | Negative | 0.1 | 0.209 | Possible IPA |
| 3 | A003 | MM | Nodule, halo | 0.1 | Negative | Negative | Negative | 0.2 | 0.225 | Possible IPA |
| 4 | C001 | ALL | Nodules, halo | Negative | Negative | Negative | 0.2 | 0.235 | Possible IPA | |
| 5 | D020 | CML, alloSCT | Nodule, cavity | 0.1 | Negative | A. flavus plus A. fumigatus | Positive for A. fumigatus (in duplicate) | 0.2 | 1.209 | Probable IPA |
| 6 | B021 | AML | Consolidation, ground glass | 0.1 | Negative | Negative | Negative | 0.3 | 0.909 | Possible IPA |
| 7 | E032 | AML | Nodule | Negative | Negative | Negative | 0.4 | 0.543 | Possible IPA | |
| 8 | F013 | AML | Nodule, halo | 0.2 | Negative | Positive for A. fumigatus (in duplicate) | 0.5 | 0.24 | Probable IPA | |
| 9 | E013 | AML | Nodule, halo | Negative | Negative | Negative | 0.6 | 3.03 | Possible IPA | |
| 10 | G09 | DLBC | Cavity | Negative | Negative | Negative | 0.7 | 3.21 | Possible IPA | |
| 11 | D017 | AML | Nodule | 0.2 | Negative | Negative | Positive for A. fumigatus (in duplicate) | 0.8 | 0.286 | Probable IPA |
| 12 | A014 | AML | Nodule, halo | 0.1 | Negative | Negative | Positive for A. fumigatus (in duplicate) | 0.8 | 0.261 | Probable IPA |
| 13 | D061 | Polycythemia vera, alloSCT | Nodules, halo | 0.1 | Negative | Negative | Negative | 0.9 | 0.769 | Possible IPA |
| 14 | G021 | AML | Nodule, halo | 0.1 | Negative | A. flavus | Positive for Aspergillus species (single PCR) | 0.9 | 0.302 | Probable IPA |
| 15 | E008 | AML, alloSCT | Consolidation | Negative | Negative | Negative | 1,0 | 0.09 | Probable IPA (possible IPA)c | |
| 16 | B015 | AML | Consolidation, ground glass | 0.7 | Negative | Negative | NA | 1,0 | 0.155 | Probable IPA (possible IPA)c |
| 17 | G019 | AML | Nodule | NA | Negative | Negative | Positive for A. fumigatus (in duplicate) | 1 | 0.04 | Probable IPA |
| 18 | A006 | Mantle cell lymphoma | Cavitation | 0.1 | Negative | Negative | Positive for A. fumigatus (in duplicate) | 1 | 0.192 | Probable IPA |
| 19 | E026 | AML | Nodule | 0.1 | Negative | Negative | Negative | 1.1 | 0.185 | Probable IPA (possible IPA)c |
| 20 | D003 | CLL | Nodules | 0.1 | Positive | A. fumigatus | Positive for A. fumigatus (in duplicate) | 1.5 | 0.011 | Probable IPA |
a
Discrepant results were defined as a VirClia GM assay (CLIA) ODI value of ≥0.200 with a Platelia GM assay (EIA) ODI value of <1.0 or an EIA ODI value of ≥1.0 with a CLIA ODI value of <0.200. AML, acute myeloid leukemia; NK-T lymphoma, natural killer T-cell lymphoma; MM, multiple myeloma; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; DLBC, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; NA, not applicable.
b
The highest serum EIA ODI value is shown.
c
For patients 15, 16, and 19, the EORTC/MSG classification changed from probable IPA to possible IPA with the exclusion of GM as a criterion.